Vytorin and Eplerenone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vytorin (ezetimibe; simvastatin) and Eplerenone (eplerenone). Common drug interactions include cardiac failure among females and myocardial infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Vytorin and Eplerenone. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Vytorin?

Vytorin has active ingredients of ezetimibe; simvastatin. It is often used in high blood cholesterol. eHealthMe is studying from 20,084 Vytorin users. Check the latest studies of Vytorin.

What is Eplerenone?

Eplerenone has active ingredients of eplerenone. It is often used in high blood pressure. eHealthMe is studying from 9,979 Eplerenone users. Check the latest studies of Eplerenone.



On Jul, 28, 2026

20 people who take Vytorin and Eplerenone together, and have interactions are studied.

Vytorin and Eplerenone drug interactions.

What are the common drug interactions of Vytorin and Eplerenone, by gender? *:

female:

  1. Cardiac failure
  2. Upper respiratory tract infection
  3. Vertigo
  4. Anxiety
  5. Cerebral thrombosis (blood clot in brain)
  6. Death
  7. Emotional distress
  8. Fear
  9. Multi-organ failure (multisystem organ failure)
  10. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

male:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Renal failure (kidney dysfunction)
  3. Asthenia (weakness)
  4. Dehydration (dryness resulting from the removal of water)
  5. Diarrhoea
  6. Disease progression
  7. Dizziness
  8. Fear
  9. Gastric disorder (disease of stomach)
  10. Hypokalaemia (low potassium)

What are the common drug interactions of Vytorin and Eplerenone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Chronic kidney disease
  2. Nephrogenic anaemia (anaemia due to kidney disease)
  3. Renal failure (kidney dysfunction)

40-49:

n/a

50-59:

  1. Cardiac failure
  2. Upper respiratory tract infection
  3. Vertigo
  4. Anxiety
  5. Cerebral thrombosis (blood clot in brain)
  6. Death
  7. Emotional distress
  8. Fear
  9. Multi-organ failure (multisystem organ failure)
  10. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

60+:

  1. Hypotension (abnormally low blood pressure)
  2. Multi-organ failure (multisystem organ failure)
  3. Fear
  4. Gastric disorder (disease of stomach)
  5. Hypokalaemia (low potassium)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Nausea (feeling of having an urge to vomit)
  9. Pain
  10. Renal failure (kidney dysfunction)

What are the existing conditions these people have? *

  1. Cardiac Failure: 5 people, 25.00%
  2. Gout (uric acid crystals building up in the body): 2 people, 10.00%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 10.00%
  4. Cardiac Failure Congestive: 2 people, 10.00%
  5. Dyspnea (difficult or laboured breathing): 2 people, 10.00%
  6. Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 10.00%
  7. Abdominal Pain Upper: 2 people, 10.00%
  8. Pain: 2 people, 10.00%
  9. Renal Cell Carcinoma (a kidney cancer): 2 people, 10.00%
  10. Sleep Disorder: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vytorin and Eplerenone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Vytorin and Eplerenone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vytorin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Eplerenone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vytorin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eplerenone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ezetimibe; simvastatin and eplerenone (the active ingredients of Vytorin and Eplerenone, respectively), and Vytorin and Eplerenone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: